Navigation Links
Scripps Research scientists develop novel test that identifies river blindness
Date:10/6/2010

LA JOLLA, CA October 6, 2010 For Immediate Release Scientists from The Scripps Research Institute have developed the first screening method that rapidly identifies individuals with active river blindness, a parasitic disease that afflicts an estimated 37 million people. The test could change the current strategy of mass treatment in areas where river blindness, also known as onchocerciasis, is suspected.

The study was published online on October 5, 2010, by the journal PLOS Neglected Tropical Diseases.

"A sensitive and reproducible diagnostic test for this disease is crucial for the success of worldwide control and elimination programs," said Kim Janda, Ph.D., a professor in the Departments of Chemistry and Immunology and Microbial Science, member of The Skaggs Institute for Chemical Biology, and director of The Worm Institute for Research and Medicine (WIRM) at Scripps Research. "This diagnostic tool could be a game-changer for how the disease will be treated in the future."

Judith Denery, Ph.D., a senior research associate in the Janda laboratory and the paper's first author, adds, "Because current tests often give false negatives, they are unreliable indicators of infection. For organizations such as the World Health Organization and others working to eliminate the disease, this lack of accuracy is frustrating, time-consuming, and costly."

A Stubborn Disease

The vast majority of onchocerciasis infections occur in sub-Saharan Africa, with the largest disease burden in rural Nigeria, and to a lesser degree in Yemen and in parts of Central and South America. Although control and elimination efforts over the last decade are bearing fruit, and large areas have a much lower infection rate than in the past, the disease still continues to cause misery for millions.

Humans acquire the disease after they are repeatedly bitten by black flies that harbor the worm, Onchocerca volvulus, which breed near fast moving rivers. When the flies bite a human host, O. volvulus larvae, called microfilariae, eventually spread throughout the body. The worms, which congregate in subcutaneous nodules, trigger an immune response that causes acute dermatitis and, if left untreated, tissue destruction that can lead to blindness.

The drug ivermectin, manufactured by Merck and distributed free in affected areas, effectively kills the larvae in most cases, and has served as the principal means of onchocerciasis control. Ivermectin must be taken twice yearly over a period of 15 to 20 years the life span of the worms.

Even with drug treatment, however, the disease takes a heavy toll.

"The number of those blinded by the disease who tend to live in areas where there is inadequate treatment is estimated to be around a quarter million people," says Scripps Research Assistant Professor Tobin Dickerson, Ph.D., one of the co-authors of the new study. "Most are unable to work and it's not uncommon to see an older person being led by a young child who acts comparable to a seeing-eye dog. Such children miss out on their own childhoods, often being pulled out of school to help an adult. In addition, fertile land near rivers that otherwise would be used for farming is often abandoned. Onchocerciasis is an insidious disease that affects both the individual and society."

The New Diagnostic Tool

To develop the test, the Scripps Research scientists used a highly sophisticated process known as metabolomics, the systematic study of the unique chemical fingerprints that specific cellular processes leave behind, in other words of their small-molecule metabolite profiles. Metabolic profiling can give a quick snapshot of the physiology of an organism.

The use of metabolomics on an African sample set comprised of 73 serum and plasma samples revealed 14 biomarkers that showed excellent discrimination between O. volvulus-positive and negative individuals. Application of these biomarkers to an additional sample set from onchocerciasis endemic areas where long-term ivermectin treatment has been successful revealed that the biomarkers could distinguish individuals with worms of compromised viability from those with active infection.

"Ultimately this technology can be expanded for the diagnosis of other filarial and neglected tropical diseases," Janda said.

Passion for Fighting Disease

The impetus for helping in the fight to eradicate river blindness came from entrepreneur and philanthropist John Moores. Moores is the founder of the River Blindness Foundation, a non-profit organization dedicated to research and treatment of onchocerciasis, and the Worm Institute for Research and Medicine at Scripps Researchwhich funded the current study with the Skaggs Institute.

"Mr. Moores conveyed his passion for fighting this disease to WIRM here at Scripps," Dickerson said. "Now, we have a tool that helps face up to one of the major challenges of medicine for this century -- true elimination and eradication of infectious disease. Not just treatment, but true eradication. In order to be able to do this we must be able to know for certain whether a disease is no longer present; only then can we declare victory."

The scientists hope to develop a diagnostic kit that can be used in the field to test for onchocerciasis and other parasitic diseases.


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert

Related biology news :

1. Scripps research team solves structure of beneficial virus
2. Scripps research team sheds light on immune system suppression
3. Scripps Florida scientists awarded $1.5M to fight major water and food parasites
4. Scripps research scientists identify compounds for stem-cell production from adult cells
5. Scripps research scientists identify blood component that turns bacteria virulent
6. Scripps research team defines new painkilling chemical pathway
7. Dolphin population stunted by fishing activities, Scripps/NOAA study finds
8. Scripps Research scientists shed light on how DNA is unwound so that its code can be read
9. Scripps scientists develop first examples of RNA that replicates itself indefinitely
10. Scripps scientists create first crystal structure of an intermediate particle in virus assembly
11. Historical photographs expose decline in Floridas reef fish, new Scripps study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... -- --> --> Fourth quarter 2015: ... 1,187% compared with fourth quarter of 2014. Gross margin was ... 30.0). Earnings per share increased to SEK 6.39 (loss: 0.49). ... 74.7). , --> --> ... M (233.6), up 1,142% compared with 2014. Gross margin was ...
(Date:2/3/2016)... Vigilant Solutions announces today that the ... Missouri solved two recent hit-and-run cases with ... Vigilant Solutions. Brian Wenberg explains, "I ... was walking out of a convenience store and witnessed an elderly male back ... striking his vehicle and leaving the scene.  In his ...
(Date:2/2/2016)... 2016  BioMEMS devices deployed in hospitals ... medical screening and diagnostic applications, such as ... that facilitate and assure continuous monitoring without ... being bolstered through new opportunities offered by ... coupled with wireless connectivity and low power ...
Breaking Biology News(10 mins):
(Date:2/11/2016)...  Vermillion, Inc. (NASDAQ: VRML ), a bio-analytical ... formation of the Steering Committee for its Pelvic Mass ... Pelvic masses can present physicians and healthcare professionals ... is ruled out, pelvic masses may include cancers of ... ovarian tumors and gastrointestinal and urinary tract masses. ...
(Date:2/11/2016)... Feb. 11, 2016  Wellcentive today announced it ... Portland, Oregon -based community care organization (CCO) ... health analytics, quality reporting and care management solutions ... its team of quality managers, analysts and care ... provider groups serving FamilyCare members. ...
(Date:2/11/2016)... 11, 2016   BioInformant announces the February ... Research Products, Opportunities, Tools, and Technologies – Market Size, ... The first and ... cell industry, BioInformant has more than a decade of ... market, by stem cell type. This powerful 175 page ...
(Date:2/10/2016)... 2016 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... that Mitsui & Co. Ltd., its partner in the ... is investing an additional CDN$25 million in the joint ... from 30% to 40%.  Mitsui will also play a ... in Sarnia , providing dedicated resources ...
Breaking Biology Technology: